title: Effects of a new calcium antagonist, manidipine, on the renal hemodynamics and the vasoactive humoral factors in patients with diabetes mellitus.
abstract: The effects of manidipine (10 mg/day for 7 days) on the renal hemodynamics and vasoactive humoral factors were examined in 6 adults with diabetes mellitus (DM). Mean duration of DM was 9 +/- 2 years; serum creatinine concentration was 0.9 +/- 0.04 mg/dL. Plasma endothelin-1 (ET-1) concentration was 5.4 +/- 0.7 pg/mL before manidipine, compared with 1.9 +/- 0.2 pg/mL in 14 controls (p = 0.03%). Systolic and mean blood pressure decreased significantly during treatment without changes in glomerular filtration rate, renal plasma flow, or filtration fraction. Renal vascular resistance tended to decrease and fractional excretion of sodium significantly increased from 1.35 +/- 0.27% to 2.06 +/- 0.47 (p = 2.96%). ET-1 significantly decreased from 5.4 +/- 0.7 pg/mL to 3.5 +/- 0.6 (p = 2.95%), while plasma angiotensin II, atrial natriuretic factor, urinary excretion rate of ET-1, and albumin excretion rate did not change. Manidipine lowers blood pressure without adversely affecting renal function in diabetic patients. Manidipine, which lowers ET-1, may protect from progressive renal injury in diabetics.
authors.affiliation: Second Department of Internal Medicine, Faculty of Medicine, Kyushu University Fukuoka, Kanagawa, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Hirakata
authors.forename: K
authors.initials: K
authors.lastname: Iino
authors.forename: I
authors.initials: I
authors.lastname: Ishida
authors.forename: M
authors.initials: M
authors.lastname: Kashiwagi
authors.forename: M
authors.initials: M
authors.lastname: Yoshinari
authors.forename: S
authors.initials: S
authors.lastname: Okuda
authors.forename: S
authors.initials: S
authors.lastname: Fujita
authors.forename: M
authors.initials: M
authors.lastname: Fujishima
mesh_terms: D000328:Adult; D000804:Angiotensin II / Q000097:blood; D009320:Atrial Natriuretic Factor / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects; D001794:Blood Pressure / Q000187:drug effects; D002121:Calcium Channel Blockers / Q000627:therapeutic use*; D048909:Diabetes Complications; D003920:Diabetes Mellitus / Q000097:blood / Q000503:physiopathology*; D004095:Dihydropyridines / Q000627:therapeutic use*; D016232:Endothelins / Q000097:blood; D005260:Female; D006801:Humans; D006973:Hypertension / Q000097:blood / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009578:Nitrobenzenes; D010879:Piperazines; D012079:Renal Circulation / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D002121:Calcium Channel Blockers; D004095:Dihydropyridines; D016232:Endothelins; D009578:Nitrobenzenes; D010879:Piperazines; D000804:Angiotensin II; C054218:manidipine; D009320:Atrial Natriuretic Factor